lncRNA HAND2 ‑AS1 mediates the downregulation of ROCK2 in hepatocellular carcinoma and inhibits cancer cell proliferation, migration and invasion.

lncRNA HAND2‑AS1 mediates the downregulation of ROCK2 in hepatocellular carcinoma and inhibits cancer cell proliferation, migration and invasion. Mol Med Rep. 2020 Jan 10;: Authors: Jiang L, He Y, Shen G, Ni J, Xia Z, Liu H, Cao Y, Li X Abstract Long noncoding (lnc)RNA HAND2‑AS1 inhibits the development of several human malignancies. The role of HAND2‑AS1 was investigated in hepatocellular carcinoma (HCC). It was found that levels of HAND2‑AS1 in serum were significantly lower, while serum levels of Rho‑associated protein kinase 2 (ROCK2) in HCC patients were significantly increased compared with hepatitis B (HB) patients and healthy controls. Decreased HAND2‑AS1 levels distinguished HCC patients but not HB patients from healthy controls. A significant negative correlation between HAND2‑AS1 and ROCK2 was found in HCC patients but not in HB patients or healthy controls. HAND2‑AS1 overexpression inhibited, while ROCK2 overexpression promoted HCC cell migration, proliferation and invasion. HAND2‑AS1 overexpression led to downregulated ROCK2 expression. ROCK2 overexpression did not significantly affect ROCK2 expression but attenuated the inhibitory effects of HAND2‑AS1 overexpression. It was therefore concluded that HAND2‑AS1 might mediate the downregulation of ROCK2 in HCC to inhibit cancer cell migration, proliferation and invasion. PMID: 31922232 [PubMed - as supplied by publisher]
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research

Related Links:

To evaluate the difference between hepatitis B virus related hepatocellular carcinoma (HBV-HCC) and non-HBV non-HCV hepatocellular carcinoma (NBNC-HCC) patients based on clinical features and prognosis.
Source: Infectious Agents and Cancer - Category: Cancer & Oncology Authors: Tags: Research Article Source Type: research
ConclusionsMVI status definitely helps select treatment options in HBV+ rHCC patients. For MVI( −) patients, RR/RFA provided better survival than TACE while for MVI(+) patients, TACE shared similar survival outcomes.Key Points• This study aimed at the determination of the optimal treatment options (ablation /resection vs TACE) in case of recurrent HBV-related HCC.• It showed that MVI status, established at primary resection of HCC, was a powerful marker for selecting the best treatment option in these patients.• In MVI(−) patients, RR/RFA achieved a better survival than TACE. In MVI(+) patients, ...
Source: European Radiology - Category: Radiology Source Type: research
n Lee Chen Tyan Hepatocellular carcinoma (HCC) is among the ten most commonly diagnosed cancers and the fourth leading cause of cancer-related death. Patients with hepatitis B virus (HBV) infection are prone to developing chronic liver diseases (i.e., fibrosis and cirrhosis), and the HBV X antigen plays an important role in the development of HCC. The difficulty in detecting HCC at the early stages is one of the main reasons that the death rate approximates the incidence rate. The regulators controlling the downstream liver protein expression from HBV infection are unclear. Mass spectrometric techniques and cu...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Hepatitis B Virus (HBV), a prototype of hepadnaviral family, is a highly oncogenic virus and its integration to human hepatocyte genome is considered to be a decisive driver of liver carcinogenesis culminating in the onset of primary liver cancer, hepatocellular carcinoma (HCC) [1]. Mechanisms of HBV integration are not well defined and those enabling the earliest (initial) virus-host DNA fusions are essentially unknown. This impedes our understanding of the initiation and molecular dynamic of progression of HBV-associated oncogenesis.
Source: Cancer Genetics and Cytogenetics - Category: Genetics & Stem Cells Authors: Source Type: research
The characteristics and associated biological functions of highly mutated genes, in which the mutation frequencies are at least 5% in HCC patients with HBV infection, are evaluated in the study, and these results could enrich our understanding of highly mutated genes and their relationships with HBV ‐related HCC. AbstractGene mutation is responsible for the development of hepatocellular carcinoma (HCC) with hepatitis B virus (HBV) infection; however, the characteristics and associated biological functions of highly mutated genes, in which the mutation frequencies are at least 5% in HCC patients with HBV infection, are no...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
The clinical manifestation of hepatocellular carcinoma (HCC) with hepatitis B virus (HBV) varies significantly between patients treated with or without nucleos(t) ide analog (NUC) therapy. To have a better und...
Source: Infectious Agents and Cancer - Category: Cancer & Oncology Authors: Tags: Research Article Source Type: research
ConclusionA substantial further reduction in cases of HCC requires a wider application of universal HBV vaccination and effective treatment of HBV- and HCV-related chronic hepatitis and cirrhosis, more effective campaigns to favor correct dietary habits and reduce alcohol consumption and the intensification of studies on HCC pathogenesis for future optimized prevention strategies.
Source: Infection - Category: Infectious Diseases Source Type: research
n Patel The hepatitis B virus (HBV) chronically infects over 250 million people worldwide and is one of the leading causes of liver cancer and hepatocellular carcinoma. HBV persistence is due in part to the highly stable HBV minichromosome or HBV covalently closed circular DNA (cccDNA) that resides in the nucleus. As HBV replication requires the help of host transcription factors to replicate, focusing on host protein–HBV genome interactions may reveal insights into new drug targets against cccDNA. The structural details on such complexes, however, remain poorly defined. In this review, the current literat...
Source: Viruses - Category: Virology Authors: Tags: Review Source Type: research
      ·Application is being reviewed under FDA ’s Real-Time Oncology Review pilot programmeBasel, 27 January 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Food and Drug Administration (FDA) for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab), for the treatment of people with unresectab le hepatocellular carcinoma (HCC) who have not received prior systemic therapy. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, wh...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
ConclusionsThis retrospective study showed that TARE therapy resulted in minimal toxicity in patients with HBV-derived HCC. Patients with CP A or BCLC A disease had superior survival outcomes compared to patients with CP B and BCLC B/C disease. These findings suggest that TARE is a viable treatment option for certain patient groups with HCC tumors secondary to HBV infection.
Source: Journal of Vascular and Interventional Radiology - Category: Radiology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Hepatitis | Hepatitis B | Hepatocellular Carcinoma | Liver Cancer | Molecular Biology